BNR — Burning Rock Biotech Share News
0.000.00%
Last trade - 00:00- $164.08m
- $102.06m
- CNY539.57m
Burning Rock Biotech gains on 2022 revenue growth forecast raise
Burning Rock Biotech - An update on 2022 revenue guidance
Brief: Burning Rock Provides An Update On 2022 Revenue Guidance
Burning Rock Biotech rises on 'breakthrough' tag for cancer detecting blood test
Burning Rock Biotech - BNR Received FDA Breakthrough Device Designation
Brief: Burning Rock Receives FDA Breakthrough Device Designation For OverC Multi-Cancer Detection Blood Test
Burning Rock Biotech Ltd reports results for the quarter ended in September - Earnings Summary
Burning Rock Biotech - Burning Rock Third Quarter 2022 Financial Results
Brief: Burning Rock Reports Third Quarter Loss Per Share $0.31
Burning Rock Biotech Ltd expected to post a loss of CNY2.35 a share - Earnings Preview
Burning Rock Biotech - Prospectus Supplement Filed with U.S. SEC
Brief: Burning Rock Biotech Ltd Files For American Depositary Shares Offering Of Up To $100 Million - SEC Filing
Burning Rock Biotech - Admission to Trading on the London Stock Exchange
Stock Exch Notice - Admission to Trading - 01/11/2022
Burning Rock Biotech - Publication of a Prospectus
Brief: Burning Rock Announces Publication Of Prospectus In Connection With Direct Listing On London Stock Exchange
Burning Rock Biotech - Publication of Registration Document
Burning Rock Biotech Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Burning Rock Reports Q2 Revenues RMB 130.8 Mln, Up By 2.8%